Holen Sie sich die Stockscreener-App
6.75
2.04%
-0.10
Schlusskurs vom Vortag:
$6.85
Offen:
$6.8
24-Stunden-Volumen:
6,804
Relative Volume:
0.09
Marktkapitalisierung:
$640.06M
Einnahmen:
$180.81M
Nettoeinkommen (Verlust:
$-160.71M
KGV:
-3.604
EPS:
-1.8729
Netto-Cashflow:
$-88.46M
1W Leistung:
-5.76%
1M Leistung:
+26.60%
6M Leistung:
-36.10%
1J Leistung:
-24.86%
1-Tages-Spanne:
$6.71
$6.80
1-Wochen-Bereich:
$6.672
$7.19
52-Wochen-Spanne:
$4.75
$12.23
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.75 | 649.54M | 180.81M | -160.71M | -88.46M | -1.8729 |
VRTX
Vertex Pharmaceuticals Inc
|
522.57 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.98 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.41 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.90 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Goldman | Neutral → Sell |
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-08-03 | Eingeleitet | H.C. Wainwright | Buy |
Valneva Se Adr Aktie (VALN) Neueste Nachrichten
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
Valneva SEADR Peer Comparison – Compare with Others - Value Research
Research Analysts Issue Forecasts for Valneva Q3 Earnings - MarketBeat
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application - Sahm
Valneva Shares Surge as Europe Begins Review of First Lyme Disease Vaccine - finance.biggo.com
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Pfizer, Valneva Lyme vaccine enters EMA review - grafa.com
Valneva SE earnings missed by $0.18, revenue fell short of estimates - Investing.com
EMA validates Pfizer-Valneva Lyme disease vaccine application By Investing.com - Investing.com India
Valneva Q2 Earnings Call Highlights - Yahoo Finance
Valneva H1 2026 slides: loss widens as Lyme hopes build - Investing.com
Earnings call transcript: Valneva H1 2026 loss widens as Lyme hopes build - Investing.com Nigeria
Valneva (NASDAQ:VALN) Shares Gap UpHere's Why - MarketBeat
Valneva stock initiated at Buy by TD Cowen on Lyme vaccine potential - Investing.com
Valneva (VALN) Edges Higher: Vaccine Developer Gains 2% as Support Holds Near $4.82Spring Pattern - vinanet.vn
Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, L - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - The National Law Review
Valneva's Trading Restriction Lifts at an Awkward Moment as Analysts Square Off Over Vaccine Prospec - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - The National Law Review
AYJ0 Forecast — Price Target — Prediction for 2027 - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - The National Law Review
A3CPD1 Forecast — Price Target — Prediction for 2027 - TradingView
Valneva SE Sponsored ADR Actuals & Estimates (NASDAQ:VALN) - TradingView
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclinePreliminary Results - dars.gov.et
VALN - Finviz
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Law firm probes Valneva over vaccine trial resu... - Pluang
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Finanzdaten der Valneva Se Adr-Aktie (VALN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):